|About Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders.
Our lead drug candidate, RP-1127, blocks the NCCa-ATP channel, reducing the formation of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.
Preclinical and clinical studies of RP-1127 have shown significant promise in the treatment of stroke, traumatic brain injury and spinal cord injury.
Our company’s mission is to save lives and improve the lives of people with these serious conditions, and in the process build shareholder value.
A Phase 2a pilot study of RP-1127 in severe ischemic stroke has been completed. A randomized, multi-center Phase 2 study of RP-1127 in severe ischemic stroke (GAMES-RP) is currently enrolling patients. A Phase 2 clinical study of RP-1127 in moderate and severe traumatic brain injury, funded by the U.S. Department of Defense in association with INTRuST is also enrolling patients.
Remedy Pharmaceuticals has built a highly experienced organization of senior professionals with successful track records in the healthcare industry, including outside advisors who are authorities in all aspects of drug discovery, clinical studies, and commercial development.
David M. Geliebter, Executive Chairman, Co-Founder
David is a serial entrepreneur with significant experience successfully starting, growing and selling businesses. David founded and ran the Carson Group, one of the world’s most successful financial information and advisory companies. Additionally, he was a founding principal and President of Evolution Capital, a healthcare investment banking firm. David is the Managing Partner of Carrot Capital Healthcare Ventures, which focuses on promising seed-stage investment opportunities across a broad spectrum of the healthcare industry.
Sven M. Jacobson, CEO, Co-Founder
Sven has co-founded five healthcare startups and has served as CEO and CFO of each at various times during their development. He has experience in cardiovascular, orthopedic, and neurological therapeutic, device and diagnostic development. Sven has been CEO of Remedy Pharmaceuticals since 2007. Currently, apart from his role of CEO of Remedy Pharmaceuticals, Sven runs the day-to-day operations of Carrot Capital and represents the fund on the board of Critical Diagnostics.